Tenofovir DF + Emtricitabine + Elvitegravir + Cobicistat

Form: Oral tablet (film-coated)

Strength: Elvitegravir – 150 mg + Cobicistat – 150 mg + Emtricitabine – 200 mg + TDF – 300 mg

Reference Brands: Stribild (US & EU)

Category: Anti Viral

Tenofovir Disoproxil Fumarate (TDF) + Emtricitabine + Elvitegravir + Cobicistat, marketed as Stribild, is a complete, once-daily, single-tablet regimen for the treatment of HIV-1 infection in treatment-naïve adults and adolescents. This fixed-dose combination includes an integrase inhibitor (Elvitegravir), two NRTIs (TDF and Emtricitabine), and a pharmacokinetic booster (Cobicistat). Approved by the US FDA and EMA, Stribild offers strong viral suppression and improved patient adherence by reducing pill burden. It must be taken with food to ensure optimal absorption. Stribild is widely used in global HIV programs, though newer TAF-based regimens like Genvoya offer improved renal and bone safety.